Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1137V | ISIN: KYG8807B1068 | Ticker-Symbol: 0TB
Tradegate
06.06.25 | 19:48
10,000 Euro
+1,01 % +0,100
1-Jahres-Chart
THERAVANCE BIOPHARMA INC Chart 1 Jahr
5-Tage-Chart
THERAVANCE BIOPHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
9,75010,00006.06.
9,75010,00006.06.

Aktuelle News zur THERAVANCE BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrTheravance and Mylan settle patent dispute with Eugia Pharma5
DiTBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises3
DiBTIG maintains buy rating on Theravance Biopharma stock2
THERAVANCE BIOPHARMA Aktie jetzt für 0€ handeln
MoTheravance hands off the last of its Trelegy royalties to GSK for $225M2
MoTheravance Biopharma To Sell Remaining Interest In Trelegy Ellipta To GSK For $225 Mln, Stock Up5
MoTheravance Biopharma, Inc. - 8-K, Current Report1
20.05.Theravance Biopharma, Inc. - 8-K, Current Report1
12.05.Theravance Biopharma, Inc. - 10-Q, Quarterly Report2
09.05.Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y1
09.05.Theravance Biopharma Q1 2025 slides: revenue growth amid widening losses2
08.05.Theravance Biopharma, Inc. - 8-K, Current Report1
08.05.Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update57YUPELRI® (revefenacin) net sales of $58.3 million, recognized by Viatris, increased 6% versus Q1 20241 TRELEGY net sales of $854M, as reported by GSK, increased...
► Artikel lesen
07.03.Theravance Biopharma, Inc. - 10-K, Annual Report-
27.02.Theravance's Q4 Loss In Line With Estimates, Sales Beat2
26.02.Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results106YUPELRI® (revefenacin) US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%,...
► Artikel lesen
26.02.Theravance Biopharma, Inc. - 8-K, Current Report-
25.02.H.C. Wainwright maintains Theravance stock Buy rating, $15 target3
12.11.24Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value542Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris...
► Artikel lesen
05.08.24Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update131Q2 2024 YUPELRI® (revefenacin) net sales of $54.5 million, recognized by Viatris, decreased 1% from Q2 20231 Viatris collaboration revenue of $14.3 million, increased 4% versus Q2 2023 Partner Viatris...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1